OBJECTIVE: We assessed the efficacy of a non- @entity902 -containing doublet chemotherapy of @entity136 and @entity1206 as induction therapy prior to surgical resection in @entity1 with stage IB-IIIA and selected stage IIIB @entity1149 ( @entity1149 ). The primary clinical end point was radiographic disease response rate, and the secondary end points were pathologic response rate, treatment-related @entity137 , surgical resectability and outcome, and overall and disease-free survival. METHODS: @entity1 underwent staging with CT of the chest and upper-abdomen, whole-body @entity419 positron emission tomography, bronchoscopy, and mediastinoscopy. The @entity1 had to have medically and surgically resectable disease. Chemotherapy consisted of @entity136 , 1,000 mg/m(2), and @entity1206 , 25 mg/m(2), administered on days 1, 8, 22, and 29. Imaging studies were repeated between days 43 and 50. Disease response was assessed by response evaluation criteria in solid @entity5 , and @entity1 with resectable disease were offered surgery between days 50 and 70. @entity1 were followed up every 3 months for 2 years with chest CT. RESULTS: Between January 2000 and March 2004, 27 @entity1 with stage IB @entity1149 , 15 @entity1 with @entity1149 , and 20 @entity1 with stage III @entity1149 were entered. After induction chemotherapy 34% (95% confidence interval [CI], 23 to 48%) had an objective radiographic response, 2% had a complete pathologic response, 90% underwent thoracotomy, and 77% underwent a complete resection. There were four deaths in the 6-week period following surgery, and there were no deaths related to chemotherapy. There were no unexpected morbidities from surgery or chemotherapy. The 1-year and 2-year overall survival rates were 80% (95% CI, 68 to 88%) and 65% (95% CI, 50 to 76%), and the median overall survival was 38.2 months. CONCLUSIONS: Induction chemotherapy with @entity136 and @entity1206 results in 1-year and 2-year survival rates and a median survival time comparable to those obtained with @entity902 -containing doublets. However, it appears to be less efficacious in terms of radiographic and pathologic response rates compared with @entity902 -containing chemotherapy doublets.

Phase II study of neoadjuvant chemotherapy with XXXX and @entity1206 in resectable @entity1149 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity419 :: ('MESH:D019788', 'Chemical') :: ['F-18 fluorodeoxyglucose'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'stage II NSCLC', 'non-small cell lung cancer'] @entity1206 :: ('MESH:C030852', 'Chemical') :: ['vinorelbine'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']
@entity136 :: (MESH:C056507,Chemical) :: ['gemcitabine']
